Free Trial

Rathbones Group PLC Sells 14,594 Shares of McKesson Corporation $MCK

McKesson logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Rathbones Group PLC cut its stake in McKesson by 26.2%, selling 14,594 shares and ending the period with 41,175 shares valued at about $33.78 million.
  • Company insiders sold a total of 3,592 shares over the last quarter — including EVP Michele Lau’s sale of 2,725 shares at an average $990 — leaving insiders with roughly 0.08% ownership.
  • McKesson beat quarterly EPS estimates ($9.34 vs. $9.19) on $106.16 billion in revenue, issued FY2026 EPS guidance of 38.80–39.20, and holds a consensus "Moderate Buy" rating with a roughly $961 price target.
  • MarketBeat previews the top five stocks to own by June 1st.

Rathbones Group PLC lowered its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 26.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,175 shares of the company's stock after selling 14,594 shares during the period. Rathbones Group PLC's holdings in McKesson were worth $33,775,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in MCK. GGM Financials LLC purchased a new stake in shares of McKesson in the 3rd quarter valued at about $25,000. State of Wyoming purchased a new position in shares of McKesson during the second quarter worth about $29,000. Hopwood Financial Services Inc. bought a new position in shares of McKesson in the third quarter worth approximately $31,000. Board of the Pension Protection Fund bought a new position in shares of McKesson in the fourth quarter worth approximately $33,000. Finally, Vermillion & White Wealth Management Group LLC purchased a new stake in McKesson in the third quarter valued at approximately $33,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at McKesson

In other McKesson news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the transaction, the executive vice president owned 3,247 shares of the company's stock, valued at $3,214,530. The trade was a 45.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the company's stock in a transaction on Friday, February 6th. The stock was sold at an average price of $955.00, for a total transaction of $313,240.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,592 shares of company stock worth $3,518,555 over the last quarter. Company insiders own 0.08% of the company's stock.

McKesson Trading Up 0.1%

Shares of NYSE:MCK opened at $885.42 on Monday. The stock has a fifty day simple moving average of $912.57 and a two-hundred day simple moving average of $846.69. The stock has a market capitalization of $108.45 billion, a price-to-earnings ratio of 25.46, a PEG ratio of 1.26 and a beta of 0.42. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter in the prior year, the firm posted $8.03 earnings per share. The business's revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts predict that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson's dividend payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

MCK has been the subject of several research analyst reports. TD Cowen lifted their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a "buy" rating in a research note on Thursday, February 5th. Robert W. Baird set a $968.00 price target on McKesson in a research note on Wednesday, January 14th. Evercore reiterated an "outperform" rating on shares of McKesson in a research report on Thursday, March 5th. Wall Street Zen upgraded shares of McKesson from a "hold" rating to a "buy" rating in a report on Sunday, March 22nd. Finally, Wells Fargo & Company lifted their target price on shares of McKesson from $914.00 to $925.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $960.93.

Get Our Latest Analysis on McKesson

McKesson Company Profile

(Free Report)

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Further Reading

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in McKesson Right Now?

Before you consider McKesson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.

While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines